OraPharma, Inc.

1深耕制药行业，更懂制药人课程简介  //  以现代制药质量管理的范围、方向和重点，以及药企公司发展为思考。由国际上相对比较成熟的质量文化的思维，做好设计，分析，系统化管理，以及高阶管理实质及资源的支持去推动质量文化建设。质量文化发展与企业发展的互利关系，高层管理领导力影响企业文化发展与质量文化的推动和执行，合规只是基本的地板，不等于质量保证，以监管角度和风险管理的观念建立合适于公司的质量系统并持续改善，建立质量文化。这过程中管理决策和推动态度关系到质量文化建设的成功与否。FDA对cGMP 2023管理重点，以及FDA认定质量文化的重要性，经过FDA检查缺现项，认为是质量文化缺失案例。最后以国内外几家公司的企业文化和质量文化案例，去看质量文化的推动。讲师简介刘妙春 老师● 有机化学背景，小分子API研究院研究员8年，担任过台湾惠氏研发及质量负责人，BMS台湾质量代表人● 担任质量负责人总资历超过15年，曾任药明生物生产质量合规负责人，东曜药业质量负责人及授权人● 经历欧盟EMA,美国FDA，土耳其，印尼，新加坡监管单位检查，主导在中生物药通过QP审计● 与国际大公司GSK, JnJ，ROCHE, ABBOT等CDMO合作经验● 担责过小分子药厂厂长超过五年，推动符合PIC/S GMP新厂建设及质量系统建设，新厂GMP认证本期课程复制下方链接观看课程内容：https://cast.263live.net/bsOniC课程费用1、课程费用：学员：500元/账号蒲公英及IPPM会员：直播：会员权益内享受免费名额回放：会员有效期内免费无限次回放2、课程付费：对公转账、微信及支付宝转账均可户    名：上海药知科技有限公司开户行：中国建设银行股份有限公司上海龙东大道支行账    号：3105 0161 4137 0000 0445发    票：增值税普通发票，内容为“会议费”或“咨询服务费”备    注：付款请注明“PGY202306”课程说明1、上课形式：线上直播 2、联系课程顾问：发放上课链接/账号/密码联系人：徐老师电话/微信：13062826101 3、设备试机：每次开课前一个工作日开放直播间，便于企业/个人进行设备调试4、课程报名：关注本公众号开课通知，随开随报咨询及建议培训咨询或其他建议徐老师：13062826101 （微信同）添加时注明“蒲公英教育”关于「蒲公英上海医药服务共创平台」蒲公英上海医药服务共创平台，于2021年成立，位于上海张江科学城，依托蒲公英Ouryao平台，授权运营蒲公英生物制药板块、国际制药项目管理协会（IPPM）中国区、生物制药国产化推进联合会（BLA）中国总部。主要业务涵盖制药全产业链专业市场活动策划及品牌推广；线上线下培训、无菌/生物药领域专业内训咨询；技术标准推进和技术项目的协助落地；高技术产品的研发及销售。蒲公英上海平台集共享办公、创新孵化、交流窗口、宣传展示、产品营销为一体，致力于成为蒲公英医药服务共创平台面向国际的窗口。蒲公英上海平台授权蒲公英旗下上海药知科技有限公司进行实体运营。药知科技（Knowhub），始于制药人，更懂制药人，已为超过100家药企提供专业服务。公司愿景：为药企提供真正需要的知识和技术服务，助力药企快速发展。关于「蒲公英 Ouryao」蒲公英（ouryao.com），创立于2012年02月，是中国医药制造领域领先的互联网生态社区，是中国医药行业极具影响力的媒体，是医药行业领先的知识平台。作为中国医药制造领域极具影响力的互联网生态社区，蒲公英每天为94万+用户会员提供专业服务，构建了以制药专业信息和知识为核心的移动生态，以蒲公英论坛、微信公众号、APP为主要支柱，孵化了药视、药文、药聘、药林、药鸽、药查、药问、药答等系列网络产品，日活跃用户、信息流稳居行业前列。作为制药行业广受关注的专业新媒体，蒲公英及旗下微信公众号关注用户突破95万+，专业媒体矩阵日均阅读量超6万，每年组织线下各类培训会议等超100场，参与人次10000+，知识传播影响力行业遥遥领先。作为制药行业领先的专业服务平台，蒲公英及其孵化的公司为200+制药企业会员单位提供知识和产品服务涵盖创投、教育、媒体、产品、园区、咨询、人才、论坛、商城、联盟十大板块，做专做精，专业技术实力领跑制药行业。蒲公英，以传播知识、传播爱心、传播力量为理念，致力于“成为更懂制药人，并能帮助制药人成长的综合服务平台”。自2021年起，蒲公英先后在天津、苏州、上海（张江+临港）、广州、深圳、成都等地设立蒲公英医药共创平台，集共享办公、创新孵化、宣传展示、商务洽谈、沙龙型会议培训、产品营销及区域办事处合作等功能为一体，打造制药人自己的区域交流平台，各区域平台立足本地辐射全国，形成具有蒲公英特色的线上线下为一体的共创家园，为中国制药人及制药行业的发展深耕助力。点击此处“阅读原文”观看直播

NEW BRUNSWICK, N.J. – July 28, 2023 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced its subsidiary LTL Management LLC (LTL) will appeal the ruling by the United States Bankruptcy Court for the District of New Jersey dismissing the bankruptcy case LTL filed.LTL commenced its bankruptcy case in good faith and in strict compliance with the Bankruptcy Code. The reorganization plan that LTL proposed with its filing committed an unprecedented $8.9 billion settlement to resolve all talc claims and is supported by counsel representing approximately 60,000 claimants.In contrast, and as the Bankruptcy Court recognized, litigating these cases in the tort system would take decades and waste billions of dollars—mainly spent on lawyers’ fees. For those few cases that actually reach trial, the Company has prevailed in the overwhelming majority, and most claimants receive nothing. By affording timely compensation for all claimants, the proposed reorganization plan offered the most equitable resolution for all claimants. LTL will appeal the Bankruptcy Court’s ruling to preserve claimants’ ability to avail themselves of that offer.“We respectfully disagree with the Bankruptcy Court’s conclusion that the ‘substantial liability’ that LTL faces from the massive volume of talc claims asserted against it does not establish ‘immediate' financial distress under the standard imposed by the Third Circuit, which itself is found nowhere in the Bankruptcy Code and is contrary to the persuasive authority from other Circuit Courts and directives of the Supreme Court of the United States,” said Erik Haas, Worldwide Vice President of Litigation. “The Bankruptcy Code does not require a business to be engulfed in ‘flames’ to seek a reorganization supported by the vast majority of claimants. As the Bankruptcy Court urged in its decision, we will continue to work with counsel representing about 60,0000 claimants to pursue a resolution of the talc claims. In the event we return to the tort system—where we have prevailed in the overwhelming majority of cases tried—we will vigorously litigate these meritless claims and bring our own actions to address the plaintiffs’ bar abuses that engendered this spurious litigation."The Company will also continue to highlight the negative impacts on U.S. businesses of meritless litigation and extreme judgments obtained by the plaintiffs’ bar through forum shopping, the distortion of scientific literature with junk science, and the unregulated and surreptitious financing of product litigation by financial institutions, including private equity and sovereign wealth funds.The Company continues to believe that the talc claims asserted against the Company are specious and lack scientific merit. Research, clinical evidence and over 40 years of studies by independent medical experts around the world continue to support the safety of our cosmetic talc. Additional information is available on www.FactsAboutTalc.com and www.LTLManagementInformation.com.About Johnson & JohnsonAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly impact health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. The information contained in this press release is for informational purposes only and should not be construed as a commitment by the Company to engage in any specific strategy or course of action. The forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of LTL Management LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: significant adverse litigation or government action, including related to product liability claims; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Neither of LTL Management LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Seasoned company builder and advisor with a proven track record of creating value in the biotechnology industry.GUILFORD, Conn., July 12, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment of David Scheer as Chairman of the Board of Directors. Mr. Scheer brings decades of experience to AI Therapeutics, having founded, built and advised multiple biotechnology companies, including Achillion, Viropharma, OraPharma and the original Esperion Therapeutics which were cumulatively acquired for nearly $7 Billion. Since 1981, Mr. Scheer has provided corporate strategic and transactional advisory services to the life sciences industry as founder and President of Scheer & Company. In this capacity, he has been integral to and, in many cases, has led the negotiation of transactions involving licensing, mergers, acquisitions and partnerships of significant economic value. Additionally, he has supported several companies through highly successful IPOs. Currently, Mr. Scheer is Chairman of the Boards of BiologicsMD, Inc., Adela, Inc., and Refactor Health. Amongst his additional advisory roles, Mr. Scheer serves as a member of the Board of Directors of BioCT and as a member of the Bioscience Innovation Advisory Committee, which oversees investments made by the $200M Connecticut Bioscience Innovation Fund. He has had significant experience in the orphan space, not only advancing innovator companies but also advising important not-for-profit entities, notably including the National Organization for Rare Disorders (NORD). He has served as a founding member of CUPA (Compassionate Use and Preapproval Access Working Group, affiliated with the Bioethics Division of NYU), member of the Impact Council of the Rutgers Global Health Institute, Vice-Chair of the Board of the Global Virus Network, and has been involved in a series of initiatives in the global health space during his tenure as a volunteer advisor for the Harvard T.H. Chan School of Public Health. Mr. Scheer holds an A.B. degree cum laude in Biochemical Sciences from Harvard College and an M.S. degree in Cell, Molecular and Developmental Biology from Yale University. “It is with great pleasure that I welcome David Scheer as Chairman of AI Therapeutics. David has a stellar track record of creating and maximizing value in the biotechnology industry. We look forward to his contributions to AI Therapeutics as the company enters an exciting phase in its development,” said Dr. Jonathan Rothberg, founder of AI Therapeutics, serial entrepreneur and Recipient of the National Medal of Technology and Innovation for inventing high speed “Next-Gen” DNA sequencing. “David brings a wealth of industry knowledge and expertise to our company, which will play an important role as our drug pipeline matures over the coming years. We look forward to working with David as we further our mission of delivering life saving medicines to patients with rare diseases,” said Dr. Brigette Roberts, Chief Executive Officer of AI Therapeutics. “In addition to welcoming David, we would also like to thank Dr. Rothberg for his many contributions to AI Therapeutics as Founder and Chairman. Dr. Rothberg is a true visionary, and we are grateful for his continued involvement as a Director of the Company.” “It is a privilege to join the AI Therapeutics Board of Directors as Chairman,” said Mr. Scheer. “I am attracted to the pipeline of potentially transformative therapeutics in the orphan and oncology arenas in addition to the strong management team and Board, and look forward to assisting in bringing these agents to patients and delivering value to shareholders.” About AI Therapeutics AI Therapeutics was founded by Dr. Jonathan Rothberg, serial entrepreneur and Recipient of the National Medal of Technology and Innovation for inventing high speed “Next-Gen” DNA sequencing, with the goal of utilizing artificial intelligence to accelerate the clinical development of drugs for rare diseases. The company is building out an expansive rare disease pipeline with the help of its Guardian Angel™ Platform, a suite of artificial intelligence tools that use deep learning to understand complex disease biology and the action of potential new therapeutics. To learn more, visit: AI Therapeutics.com. MEDIA CONTACT:info@ai-thera.com